AI Cuts Melanoma Recurrence by 49% in Moderna Trial
alex_verem · x · 2026-08-25
A 1,137-patient trial by Moderna and Merck shows that personalized mRNA cancer therapy combined with Keytruda reduced the risk of recurrence or death by 49%. The treatment uses a machine learning pipeline to select the top 34 immune-triggering mutations from thousands of candidates to create a custom mRNA shot. The post highlights the immense value of such "background" AI models in healthcare compared to consumer applications like email writing.
Related event: Merck and Moderna's AI-designed cancer vaccine cuts recurrence risk 49%(3 posts)→
More from Apps
- Ex-DeepMind Eng Lead's AI Calling Agent Fo Cut Hang-Up Rate from 80% to 20-30% — julianweisser · 2026-10-16
- Zero-latency lab-in-the-loop tests whether drug-discovery agents cheat via memorization — niloofar_mire · 2026-10-16
- fal launches Worlds for real-time creation and interaction with AI-generated worlds — Scobleizer · 2026-10-16
- Bland's new text agent Blandie shares memory with its voice AI for seamless call-to-SMS handoff — testingcatalog · 2026-10-16
- Google Search AI keeps getting better, but users want it as the primary experience — dreamwieber · 2026-10-16
- NVIDIA Nemotron 3.5 Super VL lands in Perplexity for Pro/Max and Agent API — perplexity_ai · 2026-10-16